Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. In a statement, the company said the ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a ...

Treatment with zerlasiran produced sustained reductions in lipoprotein(a) [Lp(a)] concentrations out to 1 year in adults with elevated Lp(a), extended data from the APOLLO phase 1 trial showed.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An investigational oral drug lowered lipoprotein(a) ...

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...